Motavizumab is a monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in children younger than 24 months of age at high risk of RSV-associated lower respiratory tract disease. It is administered by intramuscular injection once a month during the RSV season, which typically occurs during winter months. It is a recombinant humanized antibody that works by binding to a viral protein, inhibiting viral entry into respiratory cells and providing long-term protection against the virus. Motavizumab has been approved for use in the United States and Europe.
Motavizumab is a medication currently undergoing clinical trials and not yet commercially available for widespread use. Here's a summary of the key points:
- Purpose: Being investigated as a potential treatment for respiratory syncytial virus (RSV) infection, a common respiratory illness affecting infants and young children.
- Mechanism of action: Designed to target a specific protein on the RSV virus, potentially preventing the virus from infecting cells and causing illness.
Crucial points to remember:
- Not an approved medication: Motavizumab is still under development and has not received regulatory approval for clinical use.
- Limited information: As it's in the experimental stages, comprehensive details regarding its effectiveness, side effects, and long-term safety are not widely available.